FDA Announces Public Meeting on Levothyroxine Sodium Therapeutic Equivalence

Summary

The FDA is hosting a public workshop to discuss its regulatory standards for determining therapeutic equivalence of levothyroxine sodium drug products, involving representatives from medical societies and seeking input from patient advocacy groups and pharmaceutical sponsors.